Cross talk initiated by endothelial cells enhances migration and inhibits anoikis of squamous cell carcinoma cells through STAT3/Akt/ERK signaling

Neoplasia

Volumn 11, Issue 6, 2009, Pages 583-593

  Neiva, Kathleen G ^a   Zhang, Zhaocheng ^a   Miyazawa, Marta ^a,b   Warner, Kristy A ^a   Karl, Elisabeta ^a   Nör, Jacques E ^a,c  

^a UNIVERSITY OF MICHIGAN SCHOOL OF DENTISTRY   (United States)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR; INTERLEUKIN 6; INTERLEUKIN 8; MITOGEN ACTIVATED PROTEIN KINASE; NEUTRALIZING ANTIBODY; PROTEIN BCL 2; PROTEIN KINASE B; STAT3 PROTEIN;

ANOIKIS; ARTICLE; CARCINOMA CELL; CELL MIGRATION; ENDOTHELIUM CELL; ENZYME ACTIVATION; GENE EXPRESSION; GENE SILENCING; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; MICROVASCULATURE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; UPREGULATION;

EID: 66449127943     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.09266     Document Type: Article

References (52)

1. Folkman J (2002). Role of angiogenesis in tumor growth and metastasis. Semin Oncol 29, 15-18.
2. Zeng Q, Li S, Chepeha DB, Giordano TJ, Li J, Zhang H, Polverini PJ, Nor J, Kitajewski J, and Wang CY (2005). Crosstalk between tumor and endothelial cells promotes tumor angiogenesis by MAPK activation of Notch signaling. Cancer Cell 8, 13-23. (Pubitemid 40991811)
3. Kaneko T, Zhang Z, Mantellini MG, Karl E, Zeitlin B, Verhaegen M, Soengas MS, Lingen M, Strieter RM, Nunez G, et al. (2007). Bcl-2 orchestrates a cross-talk between endothelial and tumor cells that promotes tumor growth. Cancer Res 67, 9685-9693. (Pubitemid 47621215)
4. Chin D, Boyle GM, Porceddu S, Theile DR, Parsons PG, and Coman WB (2006). Head and neck cancer: past, present and future. Expert Rev Anticancer Ther 6, 1111-1118. (Pubitemid 44203388)
5. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, and Thun MJ (2008). Cancer statistics. CA Cancer J Clin 58, 71-96.
6. Forastiere A, Koch W, Trotti A, and Sidransky D (2001). Head and neck cancer. N Engl J Med 345, 1890-1900. (Pubitemid 33716564)
7. Mao L, Hong WK, and Papadimitrakopoulou VA (2004). Focus on head and neck cancer. Cancer Cell 5, 311-316. (Pubitemid 38482067)
8. Grandis JR, Drenning SD, Chakraborty A, Zhou MY, Zeng Q, Pitt AS, and Tweardy DJ (1998). Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor-mediated cell growth in vitro. J Clin Invest 102, 1385-1392. (Pubitemid 28467567)
9. Leeman RJ, Lui VW, and Grandis JR (2006). STAT3 as a therapeutic target in head and neck cancer. Expert Opin Biol Ther 6, 231-241. (Pubitemid 43344743)
10. Vivanco I and Sawyers CL (2002). The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2, 489-501. (Pubitemid 37328931)
11. Luo J, Manning BD, and Cantley LC (2003). Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 4, 257-262. (Pubitemid 37329790)
12. Roberts PJ and Der CJ (2007). Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 26, 3291-3310. (Pubitemid 46763022)
13. Friday BB and Adjei AA (2008). Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy. Clin Cancer Res 14, 342-346.
14. Song JI and Grandis JR (2000). STAT signaling in head and neck cancer. Oncogene 19, 2489-2495. (Pubitemid 30339204)
15. Zeng Q, Chen S, You Z, Yang F, Carey TE, Saims D, and Wang CY (2002). Hepatocyte growth factor inhibits anoikis in head and neck squamous cell carcinoma cells by activation of ERK and Akt signaling independent of NFkappa B. J Biol Chem 277, 25203-25208. (Pubitemid 34951827)
16. Chang F, Lee JT, Navolanic PM, Steelman LS, Shelton JG, Blalock WL, Franklin RA, and McCubrey JA (2003). Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. Leukemia 17, 590-603. (Pubitemid 36395654)
17. Nör JE, Christensen J, Mooney DJ, and Polverini PJ (1999). Vascular endothelial growth factor (VEGF)-mediated angiogenesis is associated with enhanced endothelial cell survival and induction of Bcl-2 expression. Am J Pathol 154, 375-384. (Pubitemid 29094088)
18. Nör JE, Christensen J, Liu J, Peters M, Mooney DJ, Strieter RM, and Polverini PJ (2001). Up-regulation of Bcl-2 in microvascular endothelial cells enhances intratumoral angiogenesis and accelerates tumor growth. Cancer Res 61, 2183-2188. (Pubitemid 32692045)
19. Karl E, Warner K, Zeitlin B, Kaneko T, Wurtzel L, Jin T, Chang J, Wang S, Wang CY, Strieter RM, et al. (2005). Bcl-2 acts in a proangiogenic signaling pathway through nuclear factor-kappaB and CXC chemokines. Cancer Res 65, 5063-5069. (Pubitemid 40827314)
20. Warner KA, Miyazawa M, Cordeiro MM, Love WJ, Pinsky MS, Neiva KG, Spalding AC, and Nör JE (2008). Endothelial cells enhance tumor cell invasion through a crosstalk mediated by CXC chemokine signaling. Neoplasia 10, 131-139.
21. Nor JE, Hu Y, Song W, Spencer DM, and Nunez G (2002). Ablation of microvessels in vivo upon dimerization of iCaspase-9. Gene Ther 9, 444-451. (Pubitemid 34428753)
22. Eisma RJ, Spiro JD, and Kreutzer DL (1997). Vascular endothelial growth factor expression in head and neck squamous cell carcinoma. Am J Surg 174, 513-517. (Pubitemid 27486016)
23. Karin M, Cao Y, Greten FR, and Li ZW (2002). NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2, 301-310. (Pubitemid 37328783)
24. Coussens LM and Werb Z (2002). Inflammation and cancer. Nature 420, 860-867. (Pubitemid 36019639)
25. Bhowmick NA and Moses HL (2005). Tumor-stroma interactions. Curr Opin Genet Dev 15, 97-101. (Pubitemid 40127637)
26. Halin S, Rudolfsson SH, Van Rooijen N, and Bergh A (2009). Extratumoral macrophages promote tumor and vascular growth in an orthotopic rat prostate tumor model. Neoplasia 11, 177-186.
27. Buettner R, Mora LB, and Jove R (2002). Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res 8, 945-954. (Pubitemid 35177340)
28. Nikitakis NG, Siavash H, and Sauk JJ (2004). Targeting the STAT pathway in head and neck cancer: recent advances and future prospects. Curr Cancer Drug Targets 4, 637-651. (Pubitemid 40013571)
29. Masuda M, Ruan HY, Ito A, Nakashima T, Toh S, Wakasaki T, Yasumatsu R, Kutratomi Y, Komune S, and Weinstein IB (2007). Signal transducers and activators of transcription 3 up-regulates vascular endothelial growth factor production and tumor angiogenesis in head and neck squamous cell carcinoma. Oral Oncol 43, 785-790. (Pubitemid 47271897)
30. Fenic I, Steger K, Gruber C, Arens C, and Woenckhaus J (2007). Analysis of PIK3CA and Akt/protein kinase B in head and neck squamous cell carcinoma. Oncol Rep 18, 253-259.
31. Opel D, Poremba C, Simon T, Debatin KM, and Fulda S (2007). Activation of Akt predicts poor outcome in neuroblastoma. Cancer Res 67, 735-745. (Pubitemid 46192214)
32. Mishima K, Inoue K, and Hayashi Y (2002). Overexpression of extracellular-signal regulated kinases on oral squamous cell carcinoma. Oral Oncol 38, 468-474. (Pubitemid 34756732)
33. Balkwill F (2004). Cancer and the chemokine network. Nat Rev Cancer 4, 540-550. (Pubitemid 38868623)
34. Vicari AP and Caux C (2002). Chemokines in cancer. Cytokine Growth Factor Rev 13, 143-154. (Pubitemid 34229389)
35. van der Horst EH, Frank BT, Chinn L, Coxon A, Li S, Polesso F, Slavin A, Ruefli-Brasse A, and Wesche H (2008). The growth factor Midkine antagonizes VEGF signaling in vitro and in vivo. Neoplasia 10, 340-347.
36. Van Snick J (1990). Interleukin-6: an overview. Annu Rev Immunol 8, 253-278. (Pubitemid 20135628)
37. Hirano T, Ishihara K, and Hibi M (2000). Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene 19, 2548-2556. (Pubitemid 30339210)
38. Hodge DR, Hurt EM, and Farrar WL (2005). The role of IL-6 and STAT3 in inflammation and cancer. Eur J Cancer 41, 2502-2512. (Pubitemid 41540626)
39. Huang S (2007). Regulation of metastases by signal transducer and activator of transcription 3 signaling pathway: clinical implications. Clin Cancer Res 13, 1362-1366. (Pubitemid 46450423)
40. Kamimura D, Ishihara K, and Hirano T (2003). IL-6 signal transduction and its physiological roles: the signal orchestration model. Rev Physiol Biochem Pharmacol 149, 1-38.
41. Squarize CH, Castilho RM, Sriuranpong V, Pinto DS Jr, and Gutkind JS (2006). Molecular cross-talk between the NFkappaB and STAT3 signaling pathways in head and neck squamous cell carcinoma. Neoplasia 8, 733-746. (Pubitemid 44465525)
42. Duffy SA, Taylor JM, Terrell JE, Islam M, Li Y, Fowler KE, Wolf GT, and Teknos TN (2008). Interleukin-6 predicts recurrence and survival among head and neck cancer patients. Cancer 113, 750-757.
43. Heimdal JH, Kross K, Klementsen B, Olofsson J, and Aarstad HJ (2008). Stimulated monocyte IL-6 secretion predicts survival of patients with head and neck squamous cell carcinoma. BMC Cancer 8, 34.
44. Koch AE, Polverini PJ, Kunkel SL, Harlow LA, DiPietro LA, Elner VM, Elner SG, and Strieter RM (1992). Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 258, 1798-1801. (Pubitemid 23087348)
45. Strieter RM, Polverini PJ, Kunkel SL, Arenberg DA, Burdick MD, Kasper J, Dzuiba J, Van Damme J, Walz A, Marriott D, et al. (1995). The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J Biol Chem 270, 27348-27357.
46. Zhu YM and Woll PJ (2005).Mitogenic effects of interleukin-8/CXCL8 on cancer cells. Future Oncol 1, 699-704.
47. Burger M, Hartmann T, Burger JA, and Schraufstatter I (2005). KSHV-GPCR and CXCR2 transforming capacity and angiogenic responses are mediated through a JAK2-STAT3-dependent pathway. Oncogene 24, 2067-2075. (Pubitemid 40516200)
48. Fuhler GM, Knol GJ, Drayer AL, and Vellenga E (2005). Impaired interleukin-8-and GROalpha-induced phosphorylation of extracellular signal-regulated kinase result in decreased migration of neutrophils from patients with myelodysplasia. J Leukoc Biol 77, 257-266. (Pubitemid 40326224)
49. Grandis JR and Tweardy DJ (1993). Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 53, 3579-3584. (Pubitemid 23229640)
50. Kijima T, Niwa H, Steinman RA, Drenning SD, Gooding WE, Wentzel AL, Xi S, and Grandis JR (2002). STAT3 activation abrogates growth factor dependence and contributes to head and neck squamous cell carcinoma tumor growth in vivo. Cell Growth Differ 3, 355-362.
51. Sriuranpong V, Park JI, Amornphimoltham P, Patel V, Nelkin BD, and Gutkind JS (2003). Epidermal growth factor receptor-independent constitutive activation of STAT3 in head and neck squamous cell carcinoma is mediated by the autocrine/paracrine stimulation of the interleukin 6/gp130 cytokine system. Cancer Res 63, 2948-2956. (Pubitemid 36667168)
52. Ha PK and Califano JA (2003). The molecular biology of mucosal field cancerization of the head and neck. Crit Rev Oral Biol Med 14, 363-369. (Pubitemid 44560790)